eClerx Services Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qmmh7vt3gno7q0d0w48f9btu.pdf

Key Takeaways


Revenue Drivers & Client Dynamics

Kapil Jain: "I wouldn't say just GenAI alone, I'm saying technology, GenAI, domain - a combination of all this together is a unique value proposition which has helped us to enhance our pipeline and the ACV of the deals."

Margin Walk & Cost Structure

Kapil Jain: "I think at this point in time, I would say that we will continue to stay in the range that we had given you 24% to 28%. And predicting beyond that, given the overall size of the book, which is about $100 million a small movement can have a big impact on the EBITDA."

GenAI, Technology & the Pipeline

Kapil Jain: "What I said was that we are not seeing deals in that area or monetization of the investments and efforts that's going in. In terms of direct that look, you have won X million dollars in GenAI business. Are we seeing the value lever in the pipeline or winning additional businesses because of the underlying technology? The answer is yes."

Delivery Footprint & Operating Model


Investment Philosophy & Capital Allocation

Kapil Jain: "We are a growth business until such time we see growth, we will continue to invest in the business. And we will stop investing when we see growth momentum coming down and I hope that doesn't happen."

Guidance & Commitments

CommitmentSpecificsTimeline
Q4 growth improvementRoll-offs came down in Q3; all else equal, Q4 performance should be better than Q3Q4 FY25
Q4 margin headwind~50 bps impact below EBITDA from new facilities; G&A flat to +10–20 bps QoQQ4 FY25
Facility cost normalizationNew facility cost absorption normalizingAt least 1 quarter away, possibly 2
EBITDA margin bandWill continue to operate within 24%–28%Ongoing
Bottom-line vs top-line gradientBottom line to have better gradient than top lineOver 2–3 years
S&M expense rangeExpected to remain in 12%–13% rangeOngoing
Operating EBITDA guidanceWill revisit giving a full-year operating EBITDA bandNext earnings call (full-year results)
EBITDA band narrowingWill consider request to narrow the 24%–28% rangeWhen coming for full-year results
BPAAS reporting definitionWill revisit definitionFY26 onwards
Peru operations launchNew subsidiary to begin operationsLate Q4 FY25
Manila Care supportExpect to start providing Care support from ManilaNot specified
Investment continuationWill continue investing as long as growth is seen; will stop when growth momentum comes downConditional on growth

Key Metrics

MetricQ3 FY25
Operating revenue (USD)$100.7 million, up 1.8% QoQ, 2.2% in constant currency, 11.2% YoY
Operating revenue (INR)₹853.8 crore, up 2.6% QoQ, 14% for the nine-month period
Total revenue₹875.2 crore, up 3.6% QoQ, 13% YoY
Other income₹21.4 crore, largely from revaluation income on INR depreciation
EBITDA₹228.1 crore, margin 26.1%, flat sequentially and YoY
PAT₹137.1 crore, margin 15.7%
EBITDA margin guidance (FY25)24% to 28%
Analytics and Automation revenue$20.8 million, up 9% QoQ
ACV of deal wins$33 million, up sequentially
Exit headcount18,642, up approximately 400 QoQ
Attrition19%
Top 10 client concentration~62%
DSO83 days, compared to 77 in the previous quarter
Seating capacity increase1,800 seats, new facilities in Mohali, Pune and Mumbai went live
Roll-off rate15% to 20% of top line
Sales and distribution expenses12% to 13% of revenue, same as last year